NanoValent Pharmaceuticals Inc.

NanoValent Pharmaceuticals is a biotechnology firm founded in 2006 to develop vaccine and cancer applications for polymerized liposomal nanoparticles (PLNs). The Company's lead product is a nanoparticle vaccine for pneumonic plaque. Animal studies have confirmed efficacy and the firm is currently completing animal toxicology and pharmacokinetic studies prior to filing an IND. The Company is currently seeking partners looking to utilize our novel nanoparticle vaccine delivery system. NanoValent is also developing surface targeted PLN drug candidates delivering anti-cancer siRNA combined with traditional chemotherapeutics. The Firm has drug delivery partnerships with the NIH, Children's Hospital of Los Angeles, Novelix Pharmaceuticals, and University of Texas Houston.

Website